Skip to content

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-526777-42-00
Enrollment
30
Registered
2026-08-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

None listed

Sponsors

Janux Therapeutics Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 20, 2026